For this study we selected human HER2, human EGFR, murine PD-L1 and murine CD8 as target antigens, but the split components can in principle be fused to any high-affinity-targeting domains that engage clinically validated targets highly expressed in the tumor microenvironment for trans-activation approaches48,49 or lymphocyte antigens for immune cell cis-activation50,51. Here, ERBB2 is linked to neoplasm.